|
Table
1. Major Drug Resistance Mutations
Nucleoside
RT Inhibitors
Drug
Zidovudine
Didanosine
Zalcitabine
Lamivudine
Abacavir
Stavudine
Multinucleoside
Resistance
Tenofovir
DAPD
|
Mutations
M41L, D67N, K70R, L210W, T215Y or F, K219Q, E, or RE44D, V118I,
H208Y
K65R, L74V, M184V
K65R, L74V, M184V
M184V or I
K65R, L74V, Y115F, M184V
K70R, T215Y or F, V75T
Q151M (usually together with A62V, V75I, 77L, F116Y)
T69SSS or T (together with 62V, 210W, 215Y or F)
K65R
K65R |
Non-nucleoside
RT Inhibitors
Delavirdine
Efavirenz
Nevirapine |
L100I,
K103N, V106A, Y181C/I, 230L, P236L
L100I, K103N, V108I,
Y188C/L/H, G190A/S, P225H, Jar
K103N, V106A, Y181C/I,
Y188C/L/H, G190A/S |
Protease
Inhibitors
Amprenavir
Indinavir
Lopinavir
Nelfinavir
Ritonavir
Saquinavir |
M46I/L,
I47V, I50V, I84V
L10I, M46I/L, I54V/L, A71V/T, V82A/T/F, I84V
D30N, N88D or S, L90M
V82A/T/F, I84V
G48V, L90M |
Mutations shown
are the major mutations most commonly selected by each drug. Additional
minor mutations may also accumulate and confer higher levels of
resistance to the drug. Likewise, mutations selected by one drug
may confer cross-resistance to another drug, but patterns of cross-resistance
are not indicated in this table. For a more complete list of mutations
see Hirsch et al JAMA 2000;283:2417-26; the resistane database at
www.hiv.lanl.gov, or the Stanford PR and RT sequence database http://hivdb.stanford.edu/hiv/.
4/15/01
Copyright 2001
by HIV and Hepatitis.com. All Rights Reserved
|
|
